|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||71.26 / 98.60|
Is this just some routine consolidation after a big run or is it an indicator of further weakness ahead?
Ark Invest has developed a series of specialized exchange-traded funds that own shares in companies involved in 'disruptive innovation.'
The momentum of acquisitions isn't stalling. Here's what names might be in the mix.
The first installment of my list includes biotech, Internet and insurance.
Here are a few reasons why these volatile names are once again on the upswing.
Will Hewlett-Packard emerge from the fog in time to tackle Amazon and Google?
These data will indicate if things are going to perk up or if we are in for more warnings.
Do your research on the underlying companies, especially during earnings season.
Investors looking to jump onto the automotive cycle should scoop up the shares and hang on for the ride.
Medidata Solutions is focusing its cloud-computing offerings on the pharmaceutical industry.
The vast bulk of S&P 500 outlooks are undershooting consensus.
These stocks look bound to get bought at every dip through year-end. You should buy up, too -- but wait for that swoon.
Jim Cramer says Medidata and Marketo represent growth opportunities in a discussion with the 'Mad Money' research director, Nicole Urken.
Covance CEO Joe Herring says the drug development company is expanding in the emerging markets as well as the cloud.
Medidata Solutions CEO Tarek Sherif discusses the company's blowout Q1 earnings report as well as the expansion of the "Clinical Cloud".